Table 2.

SWI/SNF role in hematological tumors

	Subunit	Role (TS/OG/TM)a	Malignancy	Described effect	Refs.
ATPase-Helicase	SMARCA4	TM	AML	Maintenance of leukemic cells	[51, 85, 87]
	SMARCA2/4	TM	AML	Higher dependency on SMARCA4 and SMARCA2 in leukemic cells	[88]
ARID subunits	ARID1A	TM	AML	Maintenance of leukemic cells	[51]
		TS	AML	Its loss increases cell proliferation and inhibits apoptosis of AML cells	[89]
	ARID1B	TS	AML	Its loss accelerates leukemogenesis and promotes leukemic maintenance	[36]
		TS	APL	Required for cellular differentiation	[84]
	ARID2	TS	AML	Its loss accelerates leukemogenesis	[36, 37]
		TM	AML	Maintenance of leukemic cells	[36]
Core subunits	SMARCB1	TS	–	Its loss promotes lymphomagenesis (CD8+ T cells)	[90]
		TS	CML	Its loss accelerates leukemogenesis	[91]
		TS	AML	Its loss activates oncogenic gene expression programs	[92]
	SMARCC1	TM	AML	Maintenance of leukemic cells	[51]
	SMARCD1	TM	AML	Maintenance of leukemic cells	[51]
	SMARCD2	TM	AML	Maintenance of leukemic cells	[51, 85]
Accessory subunits	ACTL6A	TM	AML	Maintenance of leukemic cells	[51]
	BCL7A	TS	DLBCL	Impairs proliferation of DLBCL cells	[86]
	BCL11A	OG	CLL, NHL, and HL	Chromosomal translocations or amplifications of this gene are found in lymphoid malignancies	[93]
		OG	AML	Acceleration of the onset of Trib1-induced AML. Its loss reduces leukemogenicity	[94]
		OG	–	Increases the onset of leukemia of either myeloid or lymphoid lineage	[95]
		TM	NKTL	Its loss increases apoptosis and reduces proliferation of NKTL cells	[96]
	BCL11B	TS	CML	Haploinsufficiency of Bcl11b promotes oncogenicity of the Bcr-Abl fusion in CML	[97]
		TS	T-ALL	Haploinsufficient tumor suppressor	[98]
		OG	ALAL	Cell self-renewal, myeloid differentiation blockage, activation of T cell genes	[99, 100]
	DPF2	TM	AML	Maintenance of leukemic cells	[85]
	BRD9	TM	ALL, MM	Its loss promotes apoptosis and sensitizes ALL and MM cells to chemotherapy.	[101]
		TM	AML	Maintenance of leukemic cells	[102]

^aTS Tumor suppressor, OG Oncogene, TM Tumor-Maintenance, ALAL acute leukemia of ambiguous lineage, ALL acute lymphoblastic leukemia, AML acute myeloid leukaemia, APL acute promyelocytic leukaemia, CLL chronic lymphocytic leukemia, CML chronic myeloid leukaemia, DLBCL diffuse large B cell lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, NKTL natural killer T cell lymphoma, NHL non-hodgkin lymphoma; -: unclassified